mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Diabetic nephropathy (DN) is among the most lethal complications that occur in type 1 and type 2 diabetics. Podocyte dysfunction is postulated to be a critical event associated with proteinuria and glomerulosclerosis in glomerular diseases including DN. However, molecular mechanisms of podocyte dysfunction in the development of DN are not well understood. Here we have shown that activity of mTOR complex 1 (mTORC1), a kinase that senses nutrient availability, was enhanced in the podocytes of diabetic animals. Further, podocyte-specific mTORC1 activation induced by ablation of an upstream negative regulator (PcKOTsc1) recapitulated many DN features, including podocyte loss, glomerular basement membrane thickening, mesangial expansion, and proteinuria in nondiabetic young and adult mice. Abnormal mTORC1 activation caused mislocalization of slit diaphragm proteins and induced an epithelial-mesenchymal transition-like phenotypic switch with enhanced ER stress in podocytes. Conversely, reduction of ER stress with a chemical chaperone significantly protected against both the podocyte phenotypic switch and podocyte loss in PcKOTsc1 mice. Finally, genetic reduction of podocyte-specific mTORC1 in diabetic animals suppressed the development of DN. These results indicate that mTORC1 activation in podocytes is a critical event in inducing DN and suggest that reduction of podocyte mTORC1 activity is a potential therapeutic strategy to prevent DN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although podocytes have high basal levels of autophagy, high mTORC1 activity is also required for these cells to maintain their function”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ulianich, L., Garbi, C., Treglia, A. S., Punzi, D., Miele, C., Raciti, G. A., Bèguinot, F., Consiglio, E., & Jeso, B. D. (2008) · Journal of Cell Science · doi:10.1242/jcs.017202 · Cited by 114
RetractedTOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Self-citationUpstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Self-citationThe Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911
Self-citationKestilä, M., Lenkkeri, U., Männikkö, M., Lamerdin, J., McCready, P., Putaala, H., Ruotsalainen, V., Morita, T., Nissinen, M., Herva, R., et al. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80057-x · Cited by 1,866
The Tuberous Sclerosis Complex
Crino, P. B., Nathanson, K. L., & Henske, E. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmra055323 · Cited by 1,793
Boute, N., Gribouval, O., Roselli, S., Benessy, F., Lee, H., Fuchshuber, A., Dahan, K., Gubler, M.-C., Niaudet, P., & Antignac, C. (2000) · Nature Genetics · doi:10.1038/74166 · Cited by 1,444
Research works printed but not linked: 2
- Zhong, Am J Respir Cell Mol Biol.
- Kouraklis, 2006, Oncol Rep., 15, 489
Cited by
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“Furthermore, recent studies have shown that either deletion or upregulation of components of the mTOR pathway, including the mTOR complexes mTORC1 and mTOR2 (210, 267), contribute to the development of diabetic nephropathy.”
BackgroundThomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Molecular mechanisms of diabetic kidney disease
Reidy, K., Kang, H. M., Hostetter, T., & Susztak, K. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72271 · Cited by 909
“Decreased activation of mTORC1 protected against DKD in mouse models (77, 78), but complete deletion of mTOR caused glomerular disease (78).”
Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis
D'Agati, V. D., Chagnac, A., de Vries, A. P. J., Levi, M., Porrini, E., Herman-Edelstein, M., & Praga, M. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.75 · Cited by 716
Mitochondrial dysfunction in diabetic kidney disease
Forbes, J. M., & Thorburn, D. R. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.9 · Cited by 634
Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c
Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., Terracciano, L., Heim, M. H., Rüegg, M. A., & Hall, M. N. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.015 · Cited by 555
“In podocytes, mTORC1 plays a role in the development of diabetic nephropathy, whereas mTORC2 appears to have a minor role (Gödel et al., 2011; Inoki et al., 2011).”
BackgroundSelf-citationRole of mTOR in podocyte function and diabetic nephropathy in humans and mice
Gödel, M., Hartleben, B., Herbach, N., Liu, S., Zschiedrich, S., Lu, S., Debreczeni-Mór, A., Lindenmeyer, M. T., Rastaldi, M.-P., Hartleben, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44774 · Cited by 547
Self-citationEndoplasmic reticulum stress, the unfolded protein response and autophagy in kidney diseases
Cybulsky, A. V. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.129 · Cited by 526
Cell Biology and Pathology of Podocytes
Greka, A., & Mundel, P. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020911-153238 · Cited by 518
Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease
de Vries, A. P. J., Ruggenenti, P., Ruan, X. Z., Praga, M., Cruzado, J. M., Bajema, I. M., D'Agati, V. D., Lamb, H. J., Barlovic, D. P., Hojs, R., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70065-8 · Cited by 500
The diverse functionality of NQO1 and its roles in redox control
Ross, D., & Siegel, D. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101950 · Cited by 499
Autophagy in kidney homeostasis and disease
Tang, C., Livingston, M. J., Liu, Z., & Dong, Z. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0309-2 · Cited by 496
Cellular and molecular mechanisms of kidney fibrosis
Djudjaj, S., & Boor, P. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.002 · Cited by 475
Dazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460
Self-citationDevelopmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog
Edeling, M., Ragi, G., Huang, S., Pavenstädt, H., & Susztak, K. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.54 · Cited by 430
Gomez, I. G., MacKenna, D. A., Johnson, B. G., Kaimal, V., Roach, A. M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75852 · Cited by 413
“Recent studies have implicated mitochondrial dysfunction, ROS production, and cell-stress pathways in podocytes directly in the development of glomerulosclerosis (37, 42), suggesting that miR-21 is an important target in glomerular disease.”
Tomita, I., Kume, S., Sugahara, S., Osawa, N., Yamahara, K., Yasuda-Yamahara, M., Takeda, N., Chin-Kanasaki, M., Kaneko, T., Mayoux, E., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.020 · Cited by 376
Molecular pathways that drive diabetic kidney disease
Mohandes, S., Doke, T., Hu, H., Mukhi, D., Dhillon, P., & Susztak, K. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165654 · Cited by 341
“mTORC1 signaling in podocytes appears to play a central role in the development of DKD (91).”
BackgroundPathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Rayego-Mateos, S., Morgado-Pascual, J. L., Opazo-Ríos, L., Guerrero-Hue, M., García-Caballero, C., Vázquez-Carballo, C., Mas, S., Sanz, A. B., Herencia, C., Mezzano, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113798 · Cited by 334
Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms
Gnudi, L., Coward, R. J. M., & Long, D. A. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.07.002 · Cited by 332
“46 Inoki, K., et al. (2011) mTORC1 activation in podocytes is a critical step in the 556 development of diabetic nephropathy in mice.”
BackgroundBidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling
Appenzeller-Herzog, C., & Hall, M. N. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.02.006 · Cited by 313
Self-citationImpaired Podocyte Autophagy Exacerbates Proteinuria in Diabetic Nephropathy
Tagawa, A., Yasuda, M., Kume, S., Yamahara, K., Nakazawa, J., Chin-Kanasaki, M., Araki, H., Araki, S.-I., Koya, D., Asanuma, K., et al. (2016) · Diabetes · doi:10.2337/db15-0473 · Cited by 315
“Interestingly, mTORC1 activity has been reported to be enhanced in podocytes of humans and animals with advanced diabetic nephropathy (50,51), suggesting that some factors in diabetic serum may activate mTORC1, suppressing podocyte autophagy.”
BackgroundAutophagy in diabetic nephropathy
Ding, Y., & Choi, M. E. (2015) · Journal of Endocrinology · doi:10.1530/joe-14-0437 · Cited by 306
“Studies carried out in mice with podocyte-specific mTORC1 activation induced by conditional deletion of an upstream negative regulator TSC1 gene products (Tsc1) in podocytes recapitulated many features of DN, such as podocyte injury and loss, proteinuria, GBM thickening, mesangial expansion, and glomerulosclerosis (In…”
BackgroundLenoir, O., Jasiek, M., Hénique, C., Guyonnet, L., Hartleben, B., Bork, T., Chipont, A., Flosseau, K., Bensaada, I., Schmitt, A., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1049799 · Cited by 296
“inhibitor CDKN1B/p27 1 70 and MTOR activation.(50,71) Therefore, HG is expected to promote podocyte injury by perturbing cell cycle regulation, and promoting hypertrophy, dedifferentiation and apoptosis.”
BackgroundSelf-citationMechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update
Bhattacharjee, N., Barma, S., Konwar, N., Dewanjee, S., & Manna, P. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.08.022 · Cited by 271
Emerging role of autophagy in kidney function, diseases and aging
Huber, T. B., Edelstein, C. L., Hartleben, B., Inoki, K., Jiang, M., Koya, D., Kume, S., Lieberthal, W., Pallet, N., Quiroga, A., et al. (2012) · Autophagy · doi:10.4161/auto.19821 · Cited by 253
“Genetic studies have begun to unveil the roles of the MTORC1-autophagy system in maintaining glomerular function.65-67 MTORC1 activity is enhanced in podocytes of diabetic animals as well as human DN. Specific activation of MTORC1 in podocytes recapitulates many DN phenotypes including glomerular membrane thickening,…”
BackgroundResultInfluentialSelf-citationMechanisms of podocyte injury and implications for diabetic nephropathy
Barutta, F., Bellini, S., & Gruden, G. (2022) · Clinical Science · doi:10.1042/cs20210625 · Cited by 221
“However, the complete ablation of mTORC1 activity in podocytes by Raptor deletion led to the early development of proteinuria in diabetic mice [235,236], indicating that while excessive mTORC1 activation is detrimental, basal mTORC1 activity is required for maintaining physiological functions of…”
Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy?
Higgins, G. C., & Coughlan, M. T. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12503 · Cited by 250
“, 2006), glomerulosclerosis and proteinuria (Godel et al., 2011; Inoki et al., 2011), and mesangial expansion (Lloberas et al.”
BackgroundAutophagy in diabetic kidney disease: regulation, pathological role and therapeutic potential
Yang, D., Livingston, M. J., Liu, Z., Dong, G., Zhang, M., Chen, J.-K., & Dong, Z. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2639-1 · Cited by 252
“In addition to rapamycin, partial suppression of mTORC1 activity in podocytes of heterozygous-Raptor knockout mice further demonstrated a strong connection of hyperactivated mTORC1 signaling with podocyte injury and proteinuria in diabetic kidneys [72, 73].”
BackgroundResearch Progress on Mechanism of Podocyte Depletion in Diabetic Nephropathy
Dai, H., Liu, Q., & Liu, B. (2017) · Journal of Diabetes Research · doi:10.1155/2017/2615286 · Cited by 239
“In general, mature podocytes had to expand the size of themselves in order to compensate for glomerular dilation, which contributed to cover the denuded region of the GBM, because they were terminal-differentiated cells, which no longer are proliferated [14, 15].”
BackgroundInfluentialEbrahim, N., Ahmed, I., Hussien, N., Dessouky, A., Farid, A., Elshazly, A., Mostafa, O., Gazzar, W., Sorour, S., Seleem, Y., et al. (2018) · Cells · doi:10.3390/cells7120226 · Cited by 235
“A growing number of studies have suggested that mTORC1 pathway inhibition with rapamycin has renoprotective effects on DN progression in models of type 1 [60] and type 2 [61] diabetes.”
BackgroundResultInhibition of AMPK Catabolic Action by GSK3
Suzuki, T., Bridges, D., Nakada, D., Skiniotis, G., Morrison, S. J., Lin, J. D., Saltiel, A. R., & Inoki, K. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.03.022 · Cited by 225
“C57BL/6J male mice, as well as muscle-specific TSC1 knockout mice created by crossing TSC1 flox/flox mice with MCK-cre transgenic mice (129S4/SvJae/C57BL/6J mix background [Inoki et al., 2011]), were fed ad lib and maintained in 12 hr light/ 12 hr dark cycles.”
MethodSelf-citationThe role of the podocyte in albumin filtration
Brinkkoetter, P. T., Ising, C., & Benzing, T. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.78 · Cited by 237
AKT2 is essential to maintain podocyte viability and function during chronic kidney disease
Canaud, G., Bienaimé, F., Viau, A., Treins, C., Baron, W., Nguyen, C., Burtin, M., Berissi, S., Giannakakis, K., Muda, A. O., et al. (2013) · Nature Medicine · doi:10.1038/nm.3313 · Cited by 222
Self-citationKato, M., Wang, M., Chen, Z., Bhatt, K., Oh, H. J., Lanting, L., Deshpande, S., Jia, Y., Lai, J. Y. C., O’Connor, C. L., et al. (2016) · Nature Communications · doi:10.1038/ncomms12864 · Cited by 221
Rapamycin for longevity: opinion article
Blagosklonny, M. V. (2019) · Aging · doi:10.18632/aging.102355 · Cited by 205
“When it is over-activated by nutrients and insulin, mTOR acts via S6K to inhibit insulin signaling, thereby causing insulin resistance [39-44].”
BackgroundProteostasis in endoplasmic reticulum—new mechanisms in kidney disease
Inagi, R., Ishimoto, Y., & Nangaku, M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.67 · Cited by 213
Podocyte–actin dynamics in health and disease
Perico, L., Conti, S., Benigni, A., & Remuzzi, G. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.127 · Cited by 209
Obesity-Mediated Autophagy Insufficiency Exacerbates Proteinuria-induced Tubulointerstitial Lesions
Yamahara, K., Kume, S., Koya, D., Tanaka, Y., Morita, Y., Chin-Kanasaki, M., Araki, H., Isshiki, K., Araki, S.-I., Haneda, M., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012111080 · Cited by 213
Mitochondrial dysfunction in diabetic kidney disease
Wei, P. Z., & Szeto, C. C. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.07.005 · Cited by 208
Roles of mTOR complexes in the kidney: implications for renal disease and transplantation
Fantus, D., Rogers, N. M., Grahammer, F., Huber, T. B., & Thomson, A. W. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.108 · Cited by 208
Self-citationThe Mechanism of Hyperglycemia-Induced Renal Cell Injury in Diabetic Nephropathy Disease: An Update
Wu, T., Ding, L., Andoh, V., Zhang, J., & Chen, L. (2023) · Life · doi:10.3390/life13020539 · Cited by 179
Maezawa, Y., Takemoto, M., & Yokote, K. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12255 · Cited by 205
Diabetic Nephropathy: a Tangled Web to Unweave
Magee, C., Grieve, D. J., Watson, C. J., & Brazil, D. P. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6755-9 · Cited by 190
“Importantly, key features of DN were recapitulated in animal models via enhanced activation of the autophagy-inhibiting gene, mechanistic target of rapamycin kinase (mTOR) [125].”
BackgroundDiabetic nephropathy: An update on pathogenesis and drug development
A/L B Vasanth Rao, V. R., Tan, S. H., Candasamy, M., & Bhattamisra, S. K. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.11.054 · Cited by 189
MicroRNA-29a Promotion of Nephrin Acetylation Ameliorates Hyperglycemia-Induced Podocyte Dysfunction
Lin, C.-L., Lee, P.-H., Hsu, Y.-C., Lei, C.-C., Ko, J.-Y., Chuang, P.-C., Huang, Y.-T., Wang, S.-Y., Wu, S.-L., Chen, Y.-S., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050527 · Cited by 193
Hu, C., Sun, L., Xiao, L., Han, Y., Fu, X., Xiong, X., Xu, X., Liu, Y., Yang, S., Liu, F., et al. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150625095407 · Cited by 199
Podocytes: the Weakest Link in Diabetic Kidney Disease?
Lin, J. S., & Susztak, K. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0735-5 · Cited by 189
Mitochondrial Hormesis and Diabetic Complications
Sharma, K. (2015) · Diabetes · doi:10.2337/db14-0874 · Cited by 193
“An increase in mTOR is a consistent finding in diabetic glomerular complications, and inhibition of mTOR leads to beneficial responses, possibly by stimulating mitochondrial biogenesis (115).”
BackgroundChronic Activation of mTOR Complex 1 Is Sufficient to Cause Hepatocellular Carcinoma in Mice
Menon, S., Yecies, J. L., Zhang, H. H., Howell, J. J., Nicholatos, J., Harputlugil, E., Bronson, R. T., Kwiatkowski, D. J., & Manning, B. D. (2012) · Science Signaling · doi:10.1126/scisignal.2002739 · Cited by 182
Self-citationUnraveling the Role of Podocyte Turnover in Glomerular Aging and Injury
Wanner, N., Hartleben, B., Herbach, N., Goedel, M., Stickel, N., Zeiser, R., Walz, G., Moeller, M. J., Grahammer, F., & Huber, T. B. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050452 · Cited by 182
Self-citationAcute Kidney Injury and Progression of Diabetic Kidney Disease
Yu, S. M.-W., & Bonventre, J. V. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.12.005 · Cited by 175
Reiser, J., & Altintas, M. M. (2016) · F1000Research · doi:10.12688/f1000research.7255.1 · Cited by 179
Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?
Marshall, C. B. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00313.2016 · Cited by 168
“Podocyte-specific activation of mTOR complex 1, a kinase that senses nutrient availability, replicates many DN features, including podocyte injury/loss, GBM thickening, and proteinuria, in the absence of hyperglycemia (73).”
BackgroundGonzález, N., Diabetes Cancer Connect Consortium, Prieto, I., del Puerto-Nevado, L., Portal-Nuñez, S., Ardura, J. A., Corton, M., Fernández-Fernández, B., Aguilera, O., Gomez-Guerrero, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14472 · Cited by 168
Renal Protective Effects of Resveratrol
Kitada, M., & Koya, D. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/568093 · Cited by 170
“Among them, the activation of mammalian target of rapamycin (mTOR) signaling pathway is involved in the pathogenesis for several kidney diseases, such as diabetic nephropathy [65–67] and the autosomal dominant polycystic kidney disease [68].”
BackgroundInhibition of MTOR Disrupts Autophagic Flux in Podocytes
Cinà, D. P., Onay, T., Paltoo, A., Li, C., Maezawa, Y., De Arteaga, J., Jurisicova, A., & Quaggin, S. E. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011070690 · Cited by 172
Sex‐ and tissue‐specific changes in mTOR signaling with age in C57 BL /6J mice
Baar, E. L., Carbajal, K. A., Ong, I. M., & Lamming, D. W. (2016) · Aging Cell · doi:10.1111/acel.12425 · Cited by 177
“, 2003), diabetes (Inoki et al., 2011; Volkers et al., 2014), and cancer (BarPeled et al.”
BackgroundGrowth-Dependent Podocyte Failure Causes Glomerulosclerosis
Fukuda, A., Chowdhury, M. A., Venkatareddy, M. P., Wang, S. Q., Nishizono, R., Suzuki, T., Wickman, L. T., Wiggins, J. E., Muchayi, T., Fingar, D., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012030271 · Cited by 170
Self-citationThe New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Lytvyn, Y., Bjornstad, P., van Raalte, D. H., Heerspink, H. L., & Cherney, D. Z. I. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz010 · Cited by 165
Lü, Q., Ji, X., Zhou, Y., Yao, X., Liu, Y., Zhang, F., & Yin, X. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.06.006 · Cited by 167
“Recent studies have demonstrated that podocyte-specific mTORC1 activation recapitulats many DN features, such as podocyte loss, glomerular basement membrane thickening, mesangial expansion and proteinuria[16,17].”
BackgroundGuan, B.-J., Krokowski, D., Majumder, M., Schmotzer, C. L., Kimball, S. R., Merrick, W. C., Koromilas, A. E., & Hatzoglou, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.543215 · Cited by 156
“However, a few reports describe concurrent mTORC1 activity and UPR induction, and in some cases, increased mTORC1 activity during ER stress was directly linked to pathogenesis (69, 70).”
BackgroundNutrient Sensing, Autophagy, and Diabetic Nephropathy
Kume, S., Thomas, M. C., & Koya, D. (2012) · Diabetes · doi:10.2337/db11-0555 · Cited by 157
“(25) Podocyte-specific raptor knockout mice Albuminuria↓, glomerular lesion↓ Inactivation of mTORC1 Gödel et al.”
BackgroundInfluentialAutophagy in kidney disease and aging: lessons from rodent models
Lenoir, O., Tharaux, P.-L., & Huber, T. B. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.014 · Cited by 148
Self-citationCybulsky, A. V. (2012) · Kidney International · doi:10.1038/ki.2012.390 · Cited by 154
Das, A., Durrant, D., Koka, S., Salloum, F. N., Xi, L., & Kukreja, R. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.521062 · Cited by 153
“Systemic administration of rapamycin ameliorates diabetes-induced renal dysfunction and blocks the onset of type 1 and T2D (20, 21).”
Differential response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy
Bentzinger, C. F., Lin, S., Romanino, K., Castets, P., Guridi, M., Summermatter, S., Handschin, C., Tintignac, L. A., Hall, M. N., & Rüegg, M. A. (2013) · Skeletal Muscle · doi:10.1186/2044-5040-3-6 · Cited by 153
“Similarly, deletion of TSC1 strongly decreases activation of PKB/Akt in cultured mouse embryonic fibroblasts [23], whereas it does not at all affect PKB/Akt phosphorylation in some tissues [58,59].”
Self-citationChoi, M. E. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034658 · Cited by 150
Hu, S., Hang, X., Wei, Y., Wang, H., Zhang, L., & Zhao, L. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01502-3 · Cited by 166
“Activation of mTORC1 in podocytes has been linked to mesangial expansion, which represents a crucial step in the development of DKD [125].”
BackgroundThe podocyte as a target for therapies—new and old
Mathieson, P. W. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.171 · Cited by 147
Tang, H., Inoki, K., Lee, M., Wright, E., Khuong, A., Khuong, A., Sugiarto, S., Garner, M., Paik, J., DePinho, R. A., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004809 · Cited by 143
“mTORC1 activity can be regulated by its components, such as raptor (27, 28), as well as its upstream inhibitor TSC1 (tuberous sclerosis complex 1), the deletion of which increases the activity of mTORC1 (29).”
BackgroundSelf-citationMammalian Target of Rapamycin Regulates Nox4-Mediated Podocyte Depletion in Diabetic Renal Injury
Eid, A. A., Ford, B. M., Bhandary, B., de Cassia Cavaglieri, R., Block, K., Barnes, J. L., Gorin, Y., Choudhury, G. G., & Abboud, H. E. (2013) · Diabetes · doi:10.2337/db12-1504 · Cited by 141
“Furthermore, podocyte-specific mTORC1 activation induced by ablation of an upstream negative regulator hamartin (TSC1) recapitulated many diabetic nephropathy features, including podocyte loss, GBM thickening, mesangial expansion, and proteinuria in nondiabetic young and adult mice (35,36).”
BackgroundThe potential role of necroptosis in inflammaging and aging
Royce, G. H., Brown‐Borg, H. M., & Deepa, S. S. (2019) · GeroScience · doi:10.1007/s11357-019-00131-w · Cited by 146
Dysregulated Autophagy Contributes to Podocyte Damage in Fabry’s Disease
Liebau, M. C., Braun, F., Höpker, K., Weitbrecht, C., Bartels, V., Müller, R., Brodesser, S., Saleem, M. A., Benzing, T. R., Schermer, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063506 · Cited by 132
“Recent compelling evidence suggests that the tight regulation of autophagy is especially important in podocytes [19,20,21,22].”
BackgroundKidney-Protective Effects of SGLT2 Inhibitors
Palmer, B. F., & Clegg, D. J. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09380822 · Cited by 137
Kogot-Levin, A., Hinden, L., Riahi, Y., Israeli, T., Tirosh, B., Cerasi, E., Mizrachi, E. B., Tam, J., Mosenzon, O., & Leibowitz, G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107954 · Cited by 126
Packer, M. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020010010 · Cited by 123
Chen, Y., Gui, D., Chen, J., He, D., Luo, Y., & Wang, N. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000362974 · Cited by 128
Yasuda, M., Tanaka, Y., Kume, S., Morita, Y., Chin-Kanasaki, M., Araki, H., Isshiki, K., Araki, S.-I., Koya, D., Haneda, M., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.001 · Cited by 123
“Growing evidence suggests that mTORC1 is pathologically activated in podocytes of the diabetic kidney in both humans and rodent models, and inactivation of mTORC1 ameliorated podocyte injury in diabetic nephropathy [33,34].”
Nox as a target for diabetic complications
Gorin, Y., & Block, K. (2013) · Clinical Science · doi:10.1042/cs20130065 · Cited by 120
Schaub, J. A., Alakwaa, F., McCown, P. J., Naik, A. S., Nair, V., Eddy, S. F., Menon, R., Otto, E. A., Demeke, D., Hartman, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164486 · Cited by 131
“These studies underscore the burden of DKD in youth-onset T2D and the lifetime risk of kidney failure and premature death in these patients.”
BackgroundInfluentialSelf-citationWu, L., Feng, Z., Cui, S., Hou, K., Tang, L., Zhou, J., Cai, G., Xie, Y., Hong, Q., Fu, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063799 · Cited by 117
“[27] proposed that abnormal mTOR activation in podocytes involved a variety of molecular reactions, including”
BackgroundInflammatory Mediators and Renal Fibrosis
Meng, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_18 · Cited by 129
Platelet Microparticles Mediate Glomerular Endothelial Injury in Early Diabetic Nephropathy
Zhang, Y., Ma, K. L., Gong, Y. X., Wang, G. H., Hu, Z. B., Liu, L., Lü, J., Chen, P. P., Lu, C., Ruan, X. Z., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018040368 · Cited by 126
Ryter, S. W., Bhatia, D., & Choi, M. E. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2018.7518 · Cited by 114
Nadarajah, R., Milagres, R., Dilauro, M., Gutsol, A. A., Xiao, F., Zimpelmann, J., Kennedy, C., Wysocki, J. A., BATLLE, D. C., & Burns, K. D. (2012) · Kidney International · doi:10.1038/ki.2012.83 · Cited by 116
“Multiple signaling pathways may mediate podocyte apoptosis in diabetes, including involvement of mammalian target of rapamycin signaling.(19) However, Ang II is recognized as a key contributor to podocyte apoptosis, via interaction with AT1 (angiotensin II receptor, type 1) receptors, and production of reactive oxygen…”
Wang, X., Gao, L., Lin, H., Song, J., Wang, J., Yin, Y., Zhao, J., Xu, X., Li, Z., & Li, L. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.02.009 · Cited by 114
“…reduced proteinuria, mesangial matrix expansion and glomerulosclerosis and suppressed the development of DN in type 1 and 2 diabetic animals (Inoki et al., 2011; Gödel et al., 2011). mTORC1 is an important upstream inhibitor of autophagy, and Cina reported that mTORC1 is activated and may…”
BackgroundSelf-citationActivation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice
Ai, D., Baez, J. M., Jiang, H., Conlon, D. M., Hernandez-Ono, A., Frank-Kamenetsky, M., Milstein, S., Fitzgerald, K., Murphy, A. J., Woo, C. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61248 · Cited by 109
Autophagy Function and Regulation in Kidney Disease
Kaushal, G. P., Chandrashekar, K., Juncos, L. A., & Shah, S. V. (2020) · Biomolecules · doi:10.3390/biom10010100 · Cited by 116
“Moreover, the upregulation of mTOR activity has been documented in the renal IR model of AKI [78], a rat model of subtotal nephrectomy [79], glomerular injury, including diabetic nephropathy [80,81], and polycystic kidney disease [82].”
BackgroundAutophagy as a Therapeutic Target in Diabetic Nephropathy
Tanaka, Y., Kume, S., Kitada, M., Kanasaki, K., Uzu, T., Maegawa, H., & Koya, D. (2012) · Experimental Diabetes Research · doi:10.1155/2012/628978 · Cited by 111
Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy
Kume, S., & Koya, D. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.6.451 · Cited by 115
“However, excessive mTORC1 inhibition also led to podocyte dysfunction [52].”
BackgroundJi, L.-Q., Chen, Y., Wang, H., Zhang, W., He, L., Wu, J.-M., & Liu, Y. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4800 · Cited by 122
Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201600293r · Cited by 104
“This is consistent with previous studies that have shown that mTOR is activated in podocytes in diabetic nephropathy (51, 52).”
BackgroundResultNutrient-sensing mTORC1 and AMPK pathways in chronic kidney diseases
Huynh, C. Q., Ryu, J., Lee, J., Inoki, A., & Inoki, K. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00648-y · Cited by 117
“Rapamycin treatment also eliminated glomerular features of DKD in mice with aberrant podocyte mTORC1 activation owing to podocyte-specific knockout of Tsc1 (refs.(8,148,200)) (Fig.”
BackgroundSelf-citationAutophagy in Diabetes: β-Cell Dysfunction, Insulin Resistance, and Complications
Barlow, A. D., & Thomas, D. (2015) · DNA and Cell Biology · doi:10.1089/dna.2014.2755 · Cited by 118
“Inoki et al. (2011) showed that mTORC1 activity was enhanced in the podocytes of diabetic animals.”
New Insights into Podocyte Biology in Glomerular Health and Disease
Assady, S., Wanner, N., Skorecki, K. L., & Huber, T. B. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017010027 · Cited by 111
Self-citationAutophagy in Kidney Health and Disease
Wang, Z., & Choi, M. E. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5363 · Cited by 100
“Conversely, reduction of mTORC1 activity in podocytes by deletion of one allele of Raptor gene in diabetic mice prevented the development of diabetic nephropathy (24, 28).”
Hydrogen Sulfide: Recent Progression and Perspectives for the Treatment of Diabetic Nephropathy
Sun, H., Wu, Z., Cao, L., Zhu, M., Liu, T.-T., Guo, L., Lin, Y., Nie, X.-W., & Bian, J. (2019) · Molecules · doi:10.3390/molecules24152857 · Cited by 107
Regulating Autophagy as a Therapeutic Target for Diabetic Nephropathy
Kitada, M., Ogura, Y., Monno, I., & Koya, D. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0879-y · Cited by 108
Metadata
- Authors
- Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., Kwiatkowski, D. J., Rastaldi, M. P., Huber, T. B., Kretzler, M., Holzman, L. B., Wiggins, R. C., & Guan, K.-L.
- Affiliations
- University of Michigan (US)
- Life Sciences Institute (SG)
- University of Basel (CH)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
- University of California San Diego (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-06-01
- Volume
- 121
- Issue
- 6
- Pages
- 2181-2196
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3104745
- OpenAlex
- W2033798110
- Cited by
- 538
- References
- 77
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 23 · 2023: 36 · 2022: 33 · 2021: 22 · 2020: 48 · 2019: 43 · 2018: 39 · 2017: 39 · 2016: 39 · 2015: 35 · 2014: 44 · 2013: 45 · 2012: 36
- FWCI
- 35.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- edoc (University of Basel)
- Funders
- National Institutes of Health (5r01dk083491-09, DK083491)
- National Cancer Institute (R01CA108941)
- National Institute of General Medical Sciences (R01GM051586, GM051586)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK083491, DK-083491, R01DK124709)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Oncology › Renal and related cancers
- Keywords
- diabetic nephropathy, mTORC1, podocytes, podocyte loss, proteinuria, glomerulosclerosis, endoplasmic reticulum stress, epithelial-mesenchymal transition, slit diaphragm proteins, TSC1, chemical chaperones, mesangial expansion, glomerular basement membrane thickening
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Regulatory-Associated Protein of mTOR, Tuberous Sclerosis Complex 1 Protein, Animals, Carrier Proteins, Cell Differentiation, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Disease Models, Animal, Endoplasmic Reticulum, Enzyme Activation, Glomerular Mesangium, Male, Membrane Proteins, Mice, Inbred C57BL, Mice, Mutant Strains, Phosphorylation, Protein Processing, Post-Translational, Proteins, Mice, Knockout, Ribosomal Protein S6 Kinases, Sirolimus, Tumor Suppressor Proteins, Multiprotein Complexes, Adaptor Proteins, Signal Transducing, Podocytes, Glomerular Basement Membrane, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.